Altimmune ( (ALT) ) has issued an announcement.
Altimmune announced its financial results for the fourth quarter and full year of 2024, highlighting significant progress in the development of pemvidutide. The company completed enrollment for the Phase 2b IMPACT trial in MASH and expects to report top-line data in Q2 2025. Additionally, Altimmune received FDA clearance for investigational new drug applications in two more indications, with Phase 2 trials slated for mid-2025. The company also strengthened its board with two new pharmaceutical industry veterans and plans to host a virtual R&D Day on March 13, 2025, to discuss further developments.
More about Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic diseases. Its primary product, pemvidutide, is a peptide-based GLP-1/glucagon dual receptor agonist aimed at treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). The company is working on expanding the therapeutic applications of pemvidutide across additional indications.
YTD Price Performance: -16.46%
Average Trading Volume: 2,563,834
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $422.5M
For an in-depth examination of ALT stock, go to TipRanks’ Stock Analysis page.